RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Point 7 seems to be a very significant one to me:

7) The finding is NOT seen with other Ampakine compounds, even when the target organ is prepared in the normal slower fashion, and fixed with the usual chemical fixatives.

My concern is that Cortex will find it difficult to determine a reason for the artifact, and the FDA will take the path of least resistance regarding future potential problems that could reflect badly on the FDA and force Cortex to switch to a backup molecule that does not have the artifact finding... Aiming4.